Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
-
By
-
Adam Feuerstein
-
June 4, 2026
-
Clinical Scorecard: Is There Greater Promise for Revolution Medicines' Pancreatic Cancer Treatment?
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Daraxonrasib as a treatment option showing near-doubling of overall survival in second-line setting. |
| Target Population | |
| Care Setting | |
Key Highlights
- Large Phase 3 study initiated for first-line treatment with three randomization arms.
- Concerns about loss of clinical equipoise in ongoing and future trials.
- Proposal for 'reverse accelerated approval' to expedite access for newly diagnosed patients.
- Daraxonrasib showed 47% and 58% overall response rates in early studies.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of metastatic pancreatic cancer with tumor progression after chemotherapy.
Management
Monitoring & Follow-up
- Monitor overall survival and progression-free survival in clinical trials.
Risks
- Potential ethical concerns regarding equipoise in clinical trials.
Patient & Prescribing Data
Patients with metastatic pancreatic cancer.
Daraxonrasib shows significant promise in improving overall survival.
Clinical Best Practices
Related Resources & Content
